Mixed Mode Chromatography Resin Market

Mixed Mode Chromatography Resin Market Analysis and Forecast by Fact.MR

• The Mixed Mode Chromatography Resin Market is expected to grow from USD 199.0 million in 2026 to USD 855.5 million by 2036, at a 15.7% CAGR.
• Driven by expanding monoclonal antibody and biologic drug manufacturing capacity, growing biopharmaceutical pipeline requiring efficient multimodal purification platforms, and increasing adoption of mixed mode resins that combine multiple separation mechanisms to reduce column steps and improve process yields.
• With cation exchange mixed mode resins accounting for 35.2% share and monoclonal antibody purification contributing 37.9% share as companies invest in next-generation ligand chemistry, high-capacity agarose matrices, and continuous chromatography compatibility.

Summary of Mixed Mode Chromatography Resin Market

• Market Snapshot
  • In 2025, the global Mixed Mode Chromatography Resin Market was valued at approximately USD 172 million.
  • The market is estimated to reach USD 199 million in 2026 and is projected to attain USD 855.5 million by 2036.
  • The mixed mode chromatography resin market is likely to expand at a CAGR of 15.7% during the forecast period.
  • The market is anticipated to create an absolute dollar opportunity of USD 656.5 million between 2026 and 2036.
  • Cation Exchange Mixed Mode Resins accounts for 35.2% of product segment share in 2026.
  • U.S. (16.9%) and China (16.5%) are the key growth markets during the forecast period.
• Demand and Growth Drivers
  • Global monoclonal antibody manufacturing capacity expansion is driving commensurate demand for purification resins, with step reduction advantages for mixed mode formats helping them gain share.
  • The increased biopharmaceutical pipeline in biosimilars, bispecific antibodies and gene therapies is generating a demand for flexible purification platforms that can accommodate multiple molecular formats.
  • Mixed mode resins combine capture and polishing steps, reducing the number of chromatography steps, and simplifying downstream purification, improving process economics.
  • The adoption of continuous bioprocessing is creating a demand for resins that can be cycled rapidly and provide reproducible results over thousands of cycles of use.
  • China, India and South Korea are seeing new resin demand from investment in emerging market biomanufacturing as facilities move from clinical to commercial production.
• Product and Segment View
  • In 2026, cation exchange mixed mode resins will hold the largest product share of 35.2% owing to their wide applicability in antibody capture and intermediate purification steps.
  • The share of the matrix material based on agarose is 44.8%, which confirms the well-established role of cross-linked agarose beads in biopharmaceutical chromatography.
  • Key segmentation includes:
  • Product: Mixed Mode Cation Exchange Resins, Mixed Mode Anion Exchange Resins, Mixed Mode Hydrophobic Resins
  • Application: Purification of monoclonal antibodies, purification of vaccines, purification of gene therapies, fractionation of plasma proteins
  • Purification Stage Capture Stage Resins, Intermediate Purification Resins, Polishing Stage Resins
  • These resins enable:
  • Multimodal separation: a two-step chromatography combining ion exchange, hydrophobic and hydrogen bonding interactions
  • Mixed mode resins can improve aggregate and host-cell protein removal compared with some conventional single-mode resin workflows.
  • Process intensification by step reduction to minimize buffer consumption, processing time and facility footprint requirements
• Geography and Competitive Outlook
  • U.S. leads at 16.9%, driven by the largest biopharmaceutical manufacturing base, CDMO capacity expansion, and strong antibody pipeline development.
  • China at 16.5% and South Korea at 16.4% reflect rapid biomanufacturing investment, biosimilar production scaling, and domestic resin development programs.
  • Germany at 15.8% is supported by EU biopharmaceutical manufacturing and academic bioprocess research.
  • Major players include Thermo Fisher Scientific, Cytiva (Danaher), Merck KGaA (MilliporeSigma), and Bio-Rad.
• Analyst Opinion
  • Shambhu Nath Jha, Principal Consultant at Fact.MR, says "Mixed mode chromatography resins have a clear processing role in biologic drug purification. Manufacturers are paying for higher selectivity, better impurity control and resin platforms that reduce downstream complexity without forcing major process redesign."

Key Growth Drivers, Constraints, and Opportunities

Key Factors Driving Growth

• Monoclonal antibody production capacity expansion, including both originator and biosimilar facilities, is the primary volume driver for mixed mode chromatography resin consumption.
• Process intensification pressure to reduce purification cost per gram of product is driving adoption of mixed mode resins that eliminate one or more conventional chromatography steps.
• Gene therapy and viral vector manufacturing growth is creating new purification challenges where mixed mode resins offer selectivity advantages over single-mode alternatives.

Key Market Constraints

• The high cost per liter of resin leads to a high consumable cost, which increases with scale of production and is a significant part of the total downstream processing cost.
• Regulatory validation requirements for process changes impose switching costs that lock manufacturers into established resin platforms for approved products.
• Supply concentration risk due to a limited number of resin suppliers (three companies account for most of the global bioprocess chromatography resin supply).

Key Opportunity Areas

• The increasing application of continuous chromatography by means of multi-column periodic counter-current systems requires resins with fast cycling and a long lifetime.
• There is a greenfield specification opportunity in the construction of biomanufacturing facilities in emerging markets where mixed mode resins can be incorporated into processes from the start.
• Development of next-generation ligand chemistry is expanding the selectivity and capacity of mixed mode resins, creating new opportunities for complex biologic purification.

Segment-wise Analysis of the Mixed Mode Chromatography Resin Market

• The market share of cation exchange mixed mode resins was 35.2% in 2026 due to its wide application in antibody purification.
• Monoclonal Antibody Purification leads the application segment with 37.9% share in 2026.
• Capture Stage Resins contribute 46.1% of purification stage share, indicating the significance of the initial capture in downstream processing efficiency.

The market is segmented by product, matrix material, application, purification stage, separation mechanism, and region. Cation exchange resins lead on antibody purification demand, while hydrophobic mixed mode resins grow fastest in polishing applications. Ion exchange interaction accounts for 42.7% of separation mechanism share.

Which Product Segment Dominates the Mixed Mode Chromatography Resin Market?

Cation exchange mixed mode resins to account for 35.2% of product segment value in 2026. Their leadership is representative of the broad application of cation exchange-hydrophobic multimodal ligands for antibody intermediate purification and polishing, where they remove aggregates, host cell proteins and DNA remaining from traditional CEX resins.

Anion exchange mixed mode resins are used in flow-through polishing applications, where negatively charged impurities are selectively captured and the target proteins are passed through. Hydrophobic mixed mode resins are designed for applications where hydrophobic interaction must be combined with other modes of selectivity to address complex separation challenges.

Which Application Segment Dominates the Mixed Mode Chromatography Resin Market?

Monoclonal Antibody Purification dominates the application segment with 37.9% share in 2026. Periodic counter-current and simulated moving bed chromatography systems facilitate near-continuous protein capture and purification, leading to increased facility throughput while reducing buffer consumption and resin inventory requirements.

This trend is supported by investment in process intensification by biopharmaceutical manufacturers to reduce cost of goods for biologic drugs. Fast cycling mixed mode resins with stable binding capacity over thousands of cycles and proven cleaning protocols are key components of continuous bioprocessing platforms. They are capturing specification-driven procurement decisions for companies that qualify their resins for compatibility with continuous chromatography.

Which Product Trend is Shaping the Next Phase of Growth in the Mixed Mode Chromatography Resin Market?

Continuous multicolumn chromatography using mixed mode resins is the primary process trend reshaping biopharmaceutical purification. Periodic counter-current and simulated moving bed chromatography systems enable near-continuous protein capture and purification, increasing facility throughput while reducing buffer consumption and resin inventory requirements.

This trend is supported by biopharmaceutical manufacturer investment in process intensification to reduce cost of goods for biologic drugs. Mixed mode resins with rapid cycling capability, consistent binding capacity across thousands of cycles, and validated cleaning protocols are essential components of continuous bioprocessing platforms. Companies that validate their resins for continuous chromatography compatibility are capturing specification-driven procurement decisions.

Regional Outlook Across Key Markets

• U.S. leads at 16.9%, driven by the largest biopharmaceutical manufacturing base, CDMO expansion, and strong antibody pipeline development.
• China at 16.5% and South Korea at 16.4% reflect rapid biomanufacturing investment and biosimilar production scaling.
• Germany at 15.8% is supported by EU pharmaceutical manufacturing capacity and academic bioprocess research.

CAGR Table

Source: Fact.MR analysis, based on proprietary forecasting model and primary research.

Mixed Mode Chromatography Resin Demand Analysis in U.S.

The U.S. Mixed Mode Chromatography Resin Market is projected to grow at a CAGR of 16.9% through 2036. FDA regulatory pathways and the largest installed base of biologic drug manufacturing capacity generate the highest single-country resin consumption. CDMO facility expansion is creating additional procurement demand beyond originator manufacturers.

• FDA approval pathway requirements create validated resin specifications that generate recurring procurement for approved products.
• CDMO capacity expansion across the U.S. is creating new mixed mode resin procurement demand as contract manufacturers scale biologic production.
• CHIPS and Science Act provisions for biomanufacturing infrastructure support domestic bioprocess capacity development.

Market Outlook for Mixed Mode Chromatography Resin in China

The China Mixed Mode Chromatography Resin Market is projected to grow at a CAGR of 16.5% through 2036. Domestic biologics capacity expansion under technology self-sufficiency policies and centralized drug procurement through VBP are reshaping the biopharmaceutical supply chain including purification consumable procurement.

• VBP procurement for biosimilar drugs is driving production volume growth that generates proportional resin consumption demand.
• Domestic resin manufacturers are developing mixed mode products to reduce import dependency for bioprocess chromatography consumables.
• Hospital biologic drug formulary expansion supports treatment volume growth that drives upstream manufacturing and resin demand.

South Korea Mixed Mode Chromatography Resin Market Growth Outlook

The South Korea Mixed Mode Chromatography Resin Market is projected to grow at a CAGR of 16.4% through 2036. Advanced biomanufacturing infrastructure and major CDMO operations by Samsung Biologics and Celltrion generate significant chromatography resin consumption. Government R&D support strengthens domestic bioprocess technology development.

• Samsung Biologics and Celltrion CDMO operations generate large-volume chromatography resin procurement for contract biologic manufacturing.
• Government biotechnology R&D support strengthens domestic bioprocess development including chromatography resin innovation.
• Biosimilar manufacturing expertise and export-oriented production create sustained demand for high-performance purification resins.

Mixed Mode Chromatography Resin Growth Assessment in India

The India Mixed Mode Chromatography Resin Market is projected to grow at a CAGR of 16.2% through 2036. Ayushman Bharat and biosimilar-friendly regulatory pathways are expanding biologic drug access. Growing domestic biomanufacturing capacity and CDMO development generate chromatography resin procurement demand.

• Biosimilar-friendly regulatory environment supports domestic biologic manufacturing that generates chromatography resin consumption.
• Private biopharmaceutical investment in manufacturing capacity expansion creates new resin procurement demand.
• Cost-effectiveness requirements in public health programs support biosimilar production that drives downstream purification consumable demand.

Germany Mixed Mode Chromatography Resin Market Growth Outlook

The Germany Mixed Mode Chromatography Resin Market is projected to grow at a CAGR of 15.8% through 2036. EU pharmaceutical manufacturing quality requirements and advanced bioprocess research infrastructure drive chromatography resin demand. EU MDR/IVDR compliance for biologic products creates validated purification process requirements.

• EU GMP requirements for biologic manufacturing create validated chromatography processes that generate recurring resin procurement.
• University bioprocess engineering programs support mixed mode resin application development and process optimization.
• Pharmaceutical manufacturing concentration in Germany generates significant bioprocess consumable demand across originator and CDMO operations.

Competitive Benchmarking and Company Positioning

Mixed Mode Chromatography Resin Market Analysis By Company

• Thermo Fisher Scientific leads through POROS and CaptureSelect resin platforms through its POROS and CaptureSelect mixed mode resin platforms, integrated bioprocess equipment portfolio, and global biopharmaceutical customer relationships.
• Cytiva (Danaher Corporation) competes through its Capto MMC and Capto adhere product lines, established market position in process-scale chromatography, and integration with its AKTA chromatography system platform.
• Merck KGaA (MilliporeSigma) serves the market through its Eshmuno mixed mode resin portfolio, process development services, and broad bioprocess consumable distribution network.

The competitive landscape is highly concentrated, with Thermo Fisher, Cytiva, and Merck controlling the majority of global mixed mode resin supply. This concentration reflects the high barriers to entry including ligand chemistry IP, regulatory validation requirements, and manufacturing scale for GMP-grade chromatography media.

Bio-Rad and Agilent Technologies serve specific application niches, while emerging resin manufacturers in China are developing domestic alternatives to reduce import dependency. Competition is shaped by binding capacity, selectivity, cycle lifetime, and regulatory support documentation that facilitates process validation.

Key Companies in the Mixed Mode Chromatography Resin Market

• Thermo Fisher Scientific, Cytiva (Danaher Corporation), Merck KGaA (MilliporeSigma), Agilent Technologies, Bio-Rad Laboratories, Inc., Tosoh Corporation, GE Healthcare (now part of Cytiva in chromatography), Ecolab / Purolite, Avantor / J.T.Baker® BAKERBOND, JSR Micro Inc. are the leading companies.

Recent Industry Developments

• Thermo Fisher Scientific - Bioprocess Chromatography Portfolio Expansion (2025)
  • Thermo Fisher Scientific continued supporting bioprocess purification through its POROS chromatography resins and CaptureSelect products. These solutions help manufacturers purify antibodies, recombinant proteins, viral vectors, and other biologics during downstream processing.
• Cytiva (Danaher) - Capto Mixed Mode Resin Platform Development (2025)
  • Cytiva continued supporting biopharmaceutical purification through its Capto MMC and Capto adhere multimodal resin platforms. These resins help manufacturers improve protein purification, antibody polishing, and process development with ÄKTA chromatography systems.
• Merck KGaA - Eshmuno Resin and Bioprocess Services Expansion (2025)
  • Merck KGaA continued supporting biologics manufacturers through its Eshmuno chromatography resin portfolio. The resin family helps improve downstream purification of monoclonal antibodies and other biomolecules by supporting impurity removal and process efficiency.

Key Companies in the Mixed Mode Chromatography Resin Market

• Thermo Fisher Scientific
• Cytiva (Danaher Corporation)
• Merck KGaA (MilliporeSigma)
• Agilent Technologies
• Bio-Rad Laboratories, Inc.
• Tosoh Corporation
• Ecolab / Purolite
• Avantor / J.T.Baker® BAKERBOND

Sources and Research References

• Cytiva. (n.d.). ReadyToProcess chromatography columns.
• International Society for Pharmaceutical Engineering. (2025). Adoption and implementation of innovative technologies in CMC. Pharmaceutical Engineering.
• Thermo Fisher Scientific. (n.d.). POROS and CaptureSelect chromatography.
• U.S. Food and Drug Administration. (2025, September). Alternative tools: Assessing drug manufacturing facilities identified in pending applications: Guidance for industry.

This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.

Key Questions This Report Addresses

• What is the estimated size of the global Mixed Mode Chromatography Resin Market in 2026, and how is it projected to grow through 2036?
• What incremental revenue opportunity is the market expected to create between 2026 and 2036?
• Which product segment holds the largest share in 2026, and what purification factors support cation exchange mixed mode resin leadership?
• How is the balance between capture and polishing stage resins expected to shift as continuous chromatography adoption grows?
• Which application segment is projected to generate the most incremental revenue through 2036?
• Which countries are projected to register the highest CAGR, and what biomanufacturing factors accelerate growth?
• How do demand patterns in the U.S. compare with China and South Korea in terms of manufacturing capacity and resin specification requirements?
• What supply concentration risks and regulatory switching costs could affect resin procurement dynamics?
• Who are the leading companies, and how are they differentiating through ligand chemistry, matrix technology, and process development support?
• What recent resin platform developments in 2025 are shaping competitive positioning in the mixed mode chromatography market?
• Which continuous processing or ligand chemistry trend is driving the next phase of growth?
• How is biosimilar manufacturing expansion in emerging markets creating new resin procurement opportunities?
• What role are process intensification, step reduction, and continuous chromatography compatibility playing in reshaping resin selection criteria?
• What demand-side drivers sustain growth, and how do they vary between monoclonal antibody and gene therapy purification?

Mixed Mode Chromatography Resin Market Definition

The mixed mode chromatography resin market covers multimodal separation media that combine two or more interaction mechanisms, including ion exchange, hydrophobic, and hydrogen bonding, in a single resin bead for biopharmaceutical purification, protein capture, polishing, and aggregate removal across monoclonal antibody, vaccine, and gene therapy manufacturing processes.

Mixed Mode Chromatography Resin Market Inclusions

• Global and regional market size and forecasts for 2026 to 2036 across product, matrix material, application, purification stage, separation mechanism, and region.
• Demand analysis based on biopharmaceutical production capacity, monoclonal antibody pipeline activity, biosimilar manufacturing volumes, and CDMO expansion.
• Competitive landscape including resin product portfolios, ligand chemistry platforms, and manufacturing capabilities of leading companies.

Mixed Mode Chromatography Resin Market Exclusions

• Single-mode chromatography resins including conventional ion exchange, hydrophobic interaction, and affinity resins without multimodal functionality.
• Protein A affinity resins sold separately from mixed mode purification systems.
• Analytical-scale chromatography columns and resins used exclusively for laboratory characterization rather than process-scale purification.

Mixed Mode Chromatography Resin Market Research Methodology

• Methodology combines secondary research from bioprocess engineering journals, biopharmaceutical manufacturing databases, and resin supplier product catalogs with primary validation.
• Market sizing covers 30+ countries with inputs including biologic drug production capacity, antibody pipeline count, CDMO facility expansion, and chromatography resin consumption.
• Primary validation is 15+ interviews with biopharmaceutical manufacturers, CDMOs, resin suppliers and bioprocess engineering consultants.